Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Gastrointestinal Stromal Tumour clinical trials

1 of 1 indexed Gastrointestinal Stromal Tumour trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Gastrointestinal Stromal Tumour: 1 US clinical trial tracked, 1 recruiting.

Gastrointestinal Stromal Tumour is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is AstraZeneca, running 1 of these trials.

Enrollment posture brief

Registry condition gastrointestinal-stromal-tumour

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Gastrointestinal Stromal (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Gastrointestinal Stromal Tumour

Gastrointestinal Stromal Tumour lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gastrointestinal Stromal Tumour on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gastrointestinal Stromal Tumour is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

AstraZeneca 1 trials

Named interventions

Most-linked intervention names on Gastrointestinal Stromal Tumour records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Trastuzumab deruxtecan Drug
1 trials

US sites by state

Facility locations filed on Gastrointestinal Stromal Tumour trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Ohio 1 trials
North Carolina 1 trials
Illinois 1 trials
Florida 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gastrointestinal Stromal Tumour page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Gastrointestinal Stromal Tumour trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AstraZeneca sponsors the most Gastrointestinal Stromal Tumour trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Stromal Tumour condition card totals 1 registered trials; most-linked intervention Trastuzumab deruxtecan; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.